An official website of the United States government
Home
Name
Ziftomenib
Alternate Names
Komzifti
Abbreviations
None
Category
Chemotherapy
Subcategory
Menin ihibitor
NSC Number
None
Primary Site
None
Histology
AML
Remarks
November 13, 2025, the FDA approved ziftomenib (Komzifti), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Coding
This drug should be coded
